European Journal of Nuclear Medicine

, Volume 25, Issue 9, pp 1341–1351

Radioimmunotherapy with alpha-emitting nuclides

  • Michael R. McDevitt
  • George Sgouros
  • Ronald D. Finn
  • John L. Humm
  • Joseph G. Jurcic
  • Steven M. Larson
  • David A. Scheinberg
Review article

DOI: 10.1007/s002590050306

Cite this article as:
McDevitt, M., Sgouros, G., Finn, R. et al. Eur J Nucl Med (1998) 25: 1341. doi:10.1007/s002590050306
  • 615 Downloads

Abstract.

This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, lead-212, actinium-225, bismuth-213, fermium-255, radium-223 and terbium-149, which at present are the most promising alpha-emitting isotopes available for human clinical use. The selective cytotoxicity offered by alpha particle-emitting radioimmunoconstructs is due to the high linear energy transfer and short particle path length of these radionuclides. Based upon the pharmacokinetics of alpha particle-emitting radioimmunoconstructs, both stochastic and conventional dosimetric methodology is discussed, as is the preclinical and initial clinical use of these radionuclides conjugated to monoclonal antibodies for the treatment of human neoplasia.

Key words: High linear energy transfer Bismuth-213 Astatine-211 Bismuth-212 Actinium-225 Alpha particle-emitting radionuclides 

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Michael R. McDevitt
    • 1
  • George Sgouros
    • 1
  • Ronald D. Finn
    • 1
  • John L. Humm
    • 1
  • Joseph G. Jurcic
    • 1
  • Steven M. Larson
    • 1
  • David A. Scheinberg
    • 1
  1. 1.Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USAUS

Personalised recommendations